Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mateus Crespo

Showing results (11-20 of 60) with videos related to

Pageof 6
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2022
Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate CancerBeshara Sheehan, Antje Neeb, Lorenzo Buroni, et al.
Cancer Treatment and Research Communications|February 7, 2021
Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation - a Single Unit ExperienceAndrea Biondo, Abhijit Pal, Ruth Riisnaes, et al.
Oncotarget|May 4, 2018
Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patientsAfroditi Nanou, Frank A W Coumans, Guus van Dalum, et al.
Clinical Genitourinary Cancer|June 2, 2016
Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular AnalysesDavid Lorente, Aurelius Omlin, Zafeiris Zafeiriou, et al.
BJU International|August 20, 2016
Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancerAndrew S McDaniel, Roberta Ferraldeschi, Rachel Krupa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2018
RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate CancerDaniel Nava Rodrigues, Nicola Casiraghi, Alessandro Romanel, et al.
Journal for Immunotherapy of Cancer|July 26, 2024
Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapyHaider Al-Janabi, Katy Moyes, Richard Allen, et al.
European Urology|June 13, 2016
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate CancerDavid Lorente, David Olmos, Joaquin Mateo, et al.
The Journal of Clinical Investigation|December 5, 2017
Differential impact of RB status on E2F1 reprogramming in human cancerChristopher McNair, Kexin Xu, Amy C Mandigo, et al.
Journal for Immunotherapy of Cancer|March 15, 2020
Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumabAnna Minchom, Wei Yuan, Mateus Crespo, et al.
Pageof 6

Showing results (11-20 of 60) with videos related to

Sort By:
Pageof 6
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2022
Prostate-Specific Membrane Antigen Expression and Response to DNA Damaging Agents in Prostate CancerBeshara Sheehan, Antje Neeb, Lorenzo Buroni, et al.
Cancer Treatment and Research Communications|February 7, 2021
Research Related Tumour Biopsies in Early-Phase Trials with Simultaneous Molecular Characterisation - a Single Unit ExperienceAndrea Biondo, Abhijit Pal, Ruth Riisnaes, et al.
Oncotarget|May 4, 2018
Circulating tumor cells, tumor-derived extracellular vesicles and plasma cytokeratins in castration-resistant prostate cancer patientsAfroditi Nanou, Frank A W Coumans, Guus van Dalum, et al.
Clinical Genitourinary Cancer|June 2, 2016
Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular AnalysesDavid Lorente, Aurelius Omlin, Zafeiris Zafeiriou, et al.
BJU International|August 20, 2016
Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancerAndrew S McDaniel, Roberta Ferraldeschi, Rachel Krupa, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 28, 2018
RB1 Heterogeneity in Advanced Metastatic Castration-Resistant Prostate CancerDaniel Nava Rodrigues, Nicola Casiraghi, Alessandro Romanel, et al.
Journal for Immunotherapy of Cancer|July 26, 2024
Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapyHaider Al-Janabi, Katy Moyes, Richard Allen, et al.
European Urology|June 13, 2016
Decline in Circulating Tumor Cell Count and Treatment Outcome in Advanced Prostate CancerDavid Lorente, David Olmos, Joaquin Mateo, et al.
The Journal of Clinical Investigation|December 5, 2017
Differential impact of RB status on E2F1 reprogramming in human cancerChristopher McNair, Kexin Xu, Amy C Mandigo, et al.
Journal for Immunotherapy of Cancer|March 15, 2020
Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumabAnna Minchom, Wei Yuan, Mateus Crespo, et al.
Pageof 6